Discovery of pyrazolopyrimidines that selectively inhibit CSF-1R kinase by iterative design, synthesis and screening against Glioblastoma cells

Dan Baillache, Teresa Valero, Alvaro Lorente-Macias, David Jonathan Bennett, Richard Elliott, Neil O Carragher, Asier Unciti-Broceta

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Glioblastoma multiforme (GBM) is the most aggressive type of brain cancer in adults, with an average life expectancy under treatment of approx. 15 months. GBM is characterised by a complex set of genetic alterations that results in significant disruption of receptor tyrosine kinase (RTK) signaling. We report here an exploration of the pyrazolo[3,4-d]pyrimidine scaffold in search for antiproliferative compounds directed to GBM treatment. Small compound libraries were synthesised and screened against GBM cells to build up structure-antiproliferative activity-relationships (SAARs) and inform further rounds of design, synthesis and screening. 76 novel compounds were generated through this iterative process that found low micromolar potencies against selected GBM lines, including patient-derived stem cells. Phenomics analysis demonstrated preferential activity against glioma cells of the mesenchymal subtype, whereas kinome screening identified Colony Stimulating Factor-1 Receptor (CSF-1R) as the lead’s target, a RTK implicated in the tumourigenesis and progression of different cancers and the immunoregulation of the GBM microenvironment.
Original languageEnglish
JournalRSC Medicinal Chemistry
Early online date11 Oct 2023
DOIs
Publication statusE-pub ahead of print - 11 Oct 2023

Fingerprint

Dive into the research topics of 'Discovery of pyrazolopyrimidines that selectively inhibit CSF-1R kinase by iterative design, synthesis and screening against Glioblastoma cells'. Together they form a unique fingerprint.

Cite this